$0.89 -$0.05 (0.0%)

04:30 PM EDT on 04/22/19

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: No stars

Current Price $0.89 Mkt Cap $34.43
Open $0.94 P/E Ratio 0.00
Prev. Close $0.89 Div. (Yield) $0.00 (0.0%)
Daily Range $0.87 - $0.94 Volume 74,375
52-Wk Range $0.66 - $1.27 Avg. Daily Vol. 12

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

22 Outperform
2 Underperform
 

All-Star Players

3 Outperform
1 Underperform
 

Wall Street

0 Outperform
1 Underperform
 

Top NASDAQ:OMED Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Tophinater (50.73)
Submitted November 17, 2014

i don't know.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:OMED VS S&P 500 (SPY)

Fools bullish on NASDAQ:OMED are also bullish on:

Fools bearish on NASDAQ:OMED are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about OMED.

Recs

0
Member Avatar DeathStock (57.76) Submitted: 4/10/2017 4:23:29 PM : Outperform Start Price: $5.51 NASDAQ:OMED Score: -118.20

Not really a fan of this company or stock but I'll take a chance with a 200M market cap in place now as it was overpriced from the IPO.

Recs

0
Member Avatar biotechf (94.72) Submitted: 7/17/2015 1:54:24 PM : Outperform Start Price: $21.43 NASDAQ:OMED Score: -145.28

Oncomed's two most promising cancer treatments are demcizumab and tarextumab targeting difficult to treat cancers. Positive clinical trial results should give these shares a boost. Both of these drugs have partnerships: demcizumab (Celgene) and tarextumab (GSK). At $21.50 per share or about 654M market capitalization the company may increase in value if phase trial results are positive.

OncoMed is conducting two randomized Phase 2 trials of demcizumab. The YOSEMITE trial is evaluating demcizumab and gemcitabine plus Abraxane in patients with first-line metastatic pancreatic cancers. The DENALI trial will assess the efficacy of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC. A Phase 1b/2 trial of demcizumab and paclitaxel in patients with platinum-resistant ovarian cancer is also ongoing.

Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The ALPINE trial is assessing tarextumab with Abraxane plus gemcitabine in first-line advanced pancreatic cancer patients. The PINNACLE trial is testing tarextumab in combination with etoposide and cisplatin and etoposide and carboplatin in first-line extensive stage small cell lung cancer patients.

Recs

0
Member Avatar sullyz0r (65.54) Submitted: 5/28/2015 2:20:24 PM : Outperform Start Price: $23.83 NASDAQ:OMED Score: -145.52

I'm actually not a huge fan of the "cancer stem cell" hypothesis, but I like this company a lot more for its notch/wnt pathway target pipeline.

Leaderboard

Find the members with the highest scoring picks in OMED.

Score Leader

TrackJimCramer

TrackJimCramer (86.92) Score: +174.33

The Score Leader is the player with the highest score across all their picks in OMED.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
wadea1 < 20 1/28/2016 Underperform 5Y $8.94 -90.04% +67.17% +157.21 0 Comment
tstapez22 28.16 3/8/2018 Outperform 5Y $2.87 -68.99% +15.83% -84.82 0 Comment
risktech 37.22 3/29/2018 Outperform 5Y $3.12 -71.47% +21.34% -92.82 0 Comment
DeathStock 57.76 4/10/2017 Outperform 5Y $5.51 -83.85% +34.35% -118.20 1 Comment
mistermiranga 99.81 7/7/2016 Outperform 5Y $12.69 -92.99% +51.45% -144.44 0 Comment
biotechf 94.72 7/17/2015 Outperform 1Y $21.43 -95.85% +49.43% -145.28 1 Comment
sullyz0r 65.54 5/28/2015 Outperform 5Y $23.83 -96.27% +49.26% -145.52 1 Comment
TruffelPig < 20 3/20/2015 Outperform 5Y $27.11 -96.72% +51.09% -147.81 0 Comment
Alonsohelps < 20 8/19/2015 Outperform 3M $21.81 -95.92% +52.00% -147.91 0 Comment
stainsolution < 20 3/31/2015 Outperform 5Y $25.78 -96.55% +53.25% -149.79 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OMED.